1
|
He J, Guo L, Xu G, Xu L, Lin S, Chen W, Wang N. Clinical and genetic investigation in Chinese patients with demyelinating Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2018; 23:216-226. [PMID: 29896895 DOI: 10.1111/jns.12277] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2018] [Revised: 06/06/2018] [Accepted: 06/11/2018] [Indexed: 11/29/2022]
Abstract
Demyelinating Charcot-Marie-Tooth disease (CMT) is the most common subtype of CMT. It is caused mainly by 17p11.2 heterozygous duplication, but also by mutations in more than 20 genes which affect development and function of Schwann cells. To investigate the profile of genes mutated and clinical features in demyelinating CMT of Chinese descent, we collected a cohort of 44 demyelinating CMT patients and screened them using multiplex ligation-dependent probe amplification (MLPA) and targeted next-generation sequencing (NGS) technology. The MLPA technology revealed that 77.3% demyelinating CMT patients harbored 17p11.2 heterozygous duplication and 6.8% patients harbored heterozygous deletion of exon 6 of MPZ gene, that was further confirmed a novel c.674_675insA mutation in MPZ gene. In the patients with 17p12 heterozygous duplication, 3 sets of independent families were discordant for the CMT phenotype within the same family. The targeted NGS technology revealed that 6 candidate mutations including 1 previously reported mutation (GDAP1: c.571C>T) and 5 novel mutations (SBF2: c.415T>C, c.619G>T, c.1258A>G; GDAP1: c.589delC; PMP22: c.318delT) were found. In conclusion, combined MLPA technique with targeted NGS, the demyelinating CMT genetic diagnostic success rate was increased.
Collapse
Affiliation(s)
- Jin He
- Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China.,Fujian Key Laboratory of Molecular Neurology, Fuzhou, China
| | - Lingling Guo
- Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
| | - Guorong Xu
- Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
| | - Liuqing Xu
- Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
| | - Shan Lin
- Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
| | - Wanjin Chen
- Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China.,Fujian Key Laboratory of Molecular Neurology, Fuzhou, China
| | - Ning Wang
- Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China.,Fujian Key Laboratory of Molecular Neurology, Fuzhou, China
| |
Collapse
|
2
|
Laššuthová P, Vill K, Erdem-Ozdamar S, Schröder JM, Topaloglu H, Horvath R, Müller-Felber W, Bansagi B, Schlotter-Weigel B, Gläser D, Neupauerová J, Sedláčková L, Staněk D, Mazanec R, Weis J, Seeman P, Senderek J. Novel SBF2 mutations and clinical spectrum of Charcot-Marie-Tooth neuropathy type 4B2. Clin Genet 2018; 94:467-472. [PMID: 30028002 DOI: 10.1111/cge.13417] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2018] [Revised: 07/04/2018] [Accepted: 07/17/2018] [Indexed: 12/27/2022]
Abstract
Biallelic SBF2 mutations cause Charcot-Marie-Tooth disease type 4B2 (CMT4B2), a sensorimotor neuropathy with autosomal recessive inheritance and association with glaucoma. Since the discovery of the gene mutation, only few additional patients have been reported. We identified seven CMT4B2 families with nine different SBF2 mutations. Revisiting genetic and clinical data from our cohort and the literature, SBF2 variants were private mutations, including exon-deletion and de novo variants. The neuropathy typically started in the first decade after normal early motor development, was predominantly motor and had a rather moderate course. Electrophysiology and nerve biopsies indicated demyelination and excess myelin outfoldings constituted a characteristic feature. While neuropathy was >90% penetrant at age 10 years, glaucoma was absent in ~40% of cases but sometimes developed with age. Consequently, SBF2 mutation analysis should not be restricted to individuals with coincident neuropathy and glaucoma, and CMT4B2 patients without glaucoma should be followed for increased intraocular pressure. The presence of exon-deletion and de novo mutations demands comprehensive mutation scanning and family studies to ensure appropriate diagnostic approaches and genetic counseling.
Collapse
Affiliation(s)
- P Laššuthová
- DNA Laboratory, Department of Pediatric Neurology, Charles University and University Hospital Motol, Prague, Czech Republic
| | - K Vill
- Department of Pediatric Neurology, Dr. v. Hauner Children's Hospital, LMU Munich, Munich, Germany
| | - S Erdem-Ozdamar
- Department of Neurology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| | - J M Schröder
- Institute of Neuropathology, RWTH Aachen University Hospital, Aachen, Germany
| | - H Topaloglu
- Department of Pediatric Neurology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| | - R Horvath
- Wellcome Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
| | - W Müller-Felber
- Department of Pediatric Neurology, Dr. v. Hauner Children's Hospital, LMU Munich, Munich, Germany
| | - B Bansagi
- Wellcome Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
| | - B Schlotter-Weigel
- Friedrich-Baur-Institute, Department of Neurology, University Hospital, LMU Munich, Munich, Germany
| | - D Gläser
- Genetikum, Center for Human Genetics, Neu-Ulm, Germany
| | - J Neupauerová
- DNA Laboratory, Department of Pediatric Neurology, Charles University and University Hospital Motol, Prague, Czech Republic
| | - L Sedláčková
- DNA Laboratory, Department of Pediatric Neurology, Charles University and University Hospital Motol, Prague, Czech Republic
| | - D Staněk
- DNA Laboratory, Department of Pediatric Neurology, Charles University and University Hospital Motol, Prague, Czech Republic
| | - R Mazanec
- Department of Neurology, Charles University and University Hospital Motol, Prague, Czech Republic
| | - J Weis
- Institute of Neuropathology, RWTH Aachen University Hospital, Aachen, Germany
| | - P Seeman
- DNA Laboratory, Department of Pediatric Neurology, Charles University and University Hospital Motol, Prague, Czech Republic
| | - J Senderek
- Friedrich-Baur-Institute, Department of Neurology, University Hospital, LMU Munich, Munich, Germany
| |
Collapse
|
3
|
Manole A, Horga A, Gamez J, Raguer N, Salvado M, San Millán B, Navarro C, Pittmann A, Reilly MM, Houlden H. SBF1 mutations associated with autosomal recessive axonal neuropathy with cranial nerve involvement. Neurogenetics 2016; 18:63-67. [PMID: 28005197 DOI: 10.1007/s10048-016-0505-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2016] [Accepted: 12/13/2016] [Indexed: 12/28/2022]
Abstract
Biallelic mutations in the SBF1 gene have been identified in one family with demyelinating Charcot-Marie-Tooth disease (CMT4B3) and two families with axonal neuropathy and additional neurological and skeletal features. Here we describe novel sequence variants in SBF1 (c.1168C>G and c.2209_2210del) as the potential causative mutations in two siblings with severe axonal neuropathy, hearing loss, facial weakness and bulbar features. Pathogenicity of these variants is supported by co-segregation and in silico analyses and evolutionary conservation. Our findings suggest that SBF1 mutations may cause a syndromic form of autosomal recessive axonal neuropathy (AR-CMT2) in addition to CMT4B3.
Collapse
Affiliation(s)
- Andreea Manole
- MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, Queen Square, London, UK.,Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK
| | - Alejandro Horga
- MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, Queen Square, London, UK
| | - Josep Gamez
- Neuromuscular Disorders Unit, Department of Neurology, Hospital Universitari Vall d'Hebron and Universitat Autònoma de Barcelona, VHIR, Passeig Vall d'Hebron, 119-135, 08035, Barcelona, Spain.
| | - Nuria Raguer
- Department of Neurophysiology, Hospital Universitari Vall d'Hebron and Universitat Autònoma de Barcelona, VHIR, Barcelona, Spain
| | - Maria Salvado
- Neuromuscular Disorders Unit, Department of Neurology, Hospital Universitari Vall d'Hebron and Universitat Autònoma de Barcelona, VHIR, Passeig Vall d'Hebron, 119-135, 08035, Barcelona, Spain
| | - Beatriz San Millán
- Department of Neuropathology, Complejo Hospitalario Universitario de Vigo, Vigo, Spain
| | - Carmen Navarro
- Department of Neuropathology, Complejo Hospitalario Universitario de Vigo, Vigo, Spain
| | - Alan Pittmann
- Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK
| | - Mary M Reilly
- MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, Queen Square, London, UK
| | - Henry Houlden
- MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, Queen Square, London, UK.,Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK
| |
Collapse
|
4
|
Schneider BP, Lai D, Shen F, Jiang G, Radovich M, Li L, Gardner L, Miller KD, O'Neill A, Sparano JA, Xue G, Foroud T, Sledge GW. Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans. Oncotarget 2016; 7:82244-82253. [PMID: 27732968 PMCID: PMC5347688 DOI: 10.18632/oncotarget.12545] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Accepted: 09/18/2016] [Indexed: 01/01/2023] Open
Abstract
PURPOSE Taxane-induced peripheral neuropathy (TIPN) is one of the most important survivorship issues for cancer patients. African Americans (AA) have previously been shown to have an increased risk for this toxicity. Germline predictive biomarkers were evaluated to help identify a priori which patients might be at extraordinarily high risk for this toxicity. EXPERIMENTAL DESIGN Whole exome sequencing was performed using germline DNA from 213 AA patients who received a standard dose and schedule of paclitaxel in the adjuvant, randomized phase III breast cancer trial, E5103. Cases were defined as those with either grade 3-4 (n=64) or grade 2-4 (n=151) TIPN and were compared to controls (n=62) that were not reported to have experienced TIPN. We retained for analysis rare variants with a minor allele frequency <3% and which were predicted to be deleterious by protein prediction programs. A gene-based, case-control analysis using SKAT was performed to identify genes that harbored an imbalance of deleterious variants associated with increased risk of TIPN. RESULTS Five genes had a p-value < 10-4 for grade 3-4 TIPN analysis and three genes had a p-value < 10-4 for the grade 2-4 TIPN analysis. For the grade 3-4 TIPN analysis, SET binding factor 2 (SBF2) was significantly associated with TIPN (p-value=4.35 x10-6). Five variants were predicted to be deleterious in SBF2. Inherited mutations in SBF2 have previously been associated with autosomal recessive, Type 4B2 Charcot-Marie-Tooth (CMT) disease. CONCLUSION Rare variants in SBF2, a CMT gene, predict an increased risk of TIPN in AA patients receiving paclitaxel.
Collapse
Affiliation(s)
| | - Dongbing Lai
- Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Fei Shen
- Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Guanglong Jiang
- Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Milan Radovich
- Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Lang Li
- Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Laura Gardner
- Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Kathy D. Miller
- Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Anne O'Neill
- Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, Massachusetts, USA
| | - Joseph A. Sparano
- Albert Einstein University, Montefiore Medical Center, Bronx, New York, USA
| | - Gloria Xue
- Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Tatiana Foroud
- Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - George W. Sledge
- Stanford University School of Medicine, Stanford, California, USA
| |
Collapse
|
5
|
Chen M, Wu J, Liang N, Tang L, Chen Y, Chen H, Wei W, Wei T, Huang H, Yi X, Qi M. Identification of a novel SBF2 frameshift mutation in charcot-marie-tooth disease type 4B2 using whole-exome sequencing. Genomics Proteomics Bioinformatics 2014; 12:221-7. [PMID: 25462154 PMCID: PMC4411414 DOI: 10.1016/j.gpb.2014.09.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/07/2014] [Revised: 09/15/2014] [Accepted: 09/18/2014] [Indexed: 12/16/2022]
Abstract
Charcot–Marie–Tooth disease type 4B2 with early-onset glaucoma (CMT4B2, OMIM 604563) is a genetically-heterogeneous childhood-onset neuromuscular disorder. Here, we report the case of a 15-year-old male adolescent with lower extremity weakness, gait abnormalities, foot deformities and early-onset glaucoma. Since clinical diagnosis alone was insufficient for providing pathogenetic evidence to indicate that the condition belonged to a consanguineous family, we applied whole-exome sequencing to samples from the patient, his parents and his younger brother, assuming that the patient’s condition is transmitted in an autosomal recessive pattern. A frame-shift mutation, c.4571delG (P.Gly1524Glufs∗42), was revealed in the CMT4B2-related gene SBF2 (also known as MTMR13, MIM 607697), and this mutation was found to be homozygous in the proband and heterozygous in his parents and younger brother. Together with the results of clinical diagnosis, this case was diagnosed as CMT4B2. Our finding further demonstrates the use of whole-exome sequencing in the diagnosis and treatment of rare diseases.
Collapse
Affiliation(s)
- Meiyan Chen
- BGI-Shenzhen, Shenzhen, Guangdong 518083, China
| | - Jing Wu
- BGI-Shenzhen, Shenzhen, Guangdong 518083, China
| | - Ning Liang
- School of Life Sciences, The Chinese University of Hong Kong, NT, Hong Kong SAR 999077, China
| | - Lihui Tang
- BGI-Shenzhen, Shenzhen, Guangdong 518083, China
| | - Yanhua Chen
- BGI-Shenzhen, Shenzhen, Guangdong 518083, China
| | | | - Wei Wei
- BGI-Shenzhen, Shenzhen, Guangdong 518083, China
| | - Tianying Wei
- Center for Genetic and Genomic Medicine, Zhejiang University School of Medicine, First Affiliated Hospital and James D. Watson Institute of Genome Sciences, Hangzhou 310006, China
| | - Hui Huang
- BGI-Shenzhen, Shenzhen, Guangdong 518083, China
| | - Xin Yi
- BGI-Shenzhen, Shenzhen, Guangdong 518083, China.
| | - Ming Qi
- BGI-Shenzhen, Shenzhen, Guangdong 518083, China; Center for Genetic and Genomic Medicine, Zhejiang University School of Medicine, First Affiliated Hospital and James D. Watson Institute of Genome Sciences, Hangzhou 310006, China; Department of Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA.
| |
Collapse
|